coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume
NN6019-4958
Phase 3 small_molecule active
Quick answer
coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume for Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active